www.fdanews.com/articles/187588-mercks-keytruda-gets-priority-review-status
![](https://www.fdanews.com/ext/resources/test/Merck.gif?t=1434062647&width=430)
Merck’s Keytruda Gets Priority Review Status
July 12, 2018
The FDA granted priority review for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 immunotherapy used in the treatment of certain cancers.
Merck has more than 10 studies investigating Keytruda in gastrointestinal cancers, including hepatocellular carcinoma.
A humanized monoclonal antibody, Keytruda works by bolstering the body’s ability to detect and combat tumor cells. It blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thus activating T-cells.